Literature DB >> 34071371

Molecular Genetics of Conjunctival Melanoma and Prognostic Value of TERT Promoter Mutation Analysis.

Natasha M van Poppelen1,2, Jolique A van Ipenburg3,4, Quincy van den Bosch3, Jolanda Vaarwater1,2, Tom Brands1,2, Bert Eussen1,2, Frank Magielsen2, Hendrikus J Dubbink3, Dion Paridaens1,5, Erwin Brosens2, Nicole Naus1, Annelies de Klein2, Emine Kiliç1, Robert M Verdijk3,5,6.   

Abstract

The aim of this study was exploration of the genetic background of conjunctival melanoma (CM) and correlation with recurrent and metastatic disease. Twenty-eight CM from the Rotterdam Ocular Melanoma Study group were collected and DNA was isolated from the formalin-fixed paraffin embedded tissue. Targeted next-generation sequencing was performed using a panel covering GNAQ, GNA11, EIF1AX, BAP1, BRAF, NRAS, c-KIT, PTEN, SF3B1, and TERT genes. Recurrences and metastasis were present in eight (29%) and nine (32%) CM cases, respectively. TERT promoter mutations were most common (54%), but BRAF (46%), NRAS (21%), BAP1 (18%), PTEN (14%), c-KIT (7%), and SF3B1 (4%) mutations were also observed. No mutations in GNAQ, GNA11, and EIF1AX were found. None of the mutations was significantly associated with recurrent disease. Presence of a TERT promoter mutation was associated with metastatic disease (p-value = 0.008). Based on our molecular findings, CM comprises a separate entity within melanoma, although there are overlapping molecular features with uveal melanoma, such as the presence of BAP1 and SF3B1 mutations. This warrants careful interpretation of molecular data, in the light of clinical findings. About three quarter of CM contain drug-targetable mutations, and TERT promoter mutations are correlated to metastatic disease in CM.

Entities:  

Keywords:  TERT promotor mutation; conjunctiva; melanoma; molecular medicine; prognosis

Year:  2021        PMID: 34071371     DOI: 10.3390/ijms22115784

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  41 in total

1.  Clinical correlates of NRAS and BRAF mutations in primary human melanoma.

Authors:  Julie A Ellerhorst; Victoria R Greene; Suhendan Ekmekcioglu; Carla L Warneke; Marcella M Johnson; Carolyn P Cooke; Li-E Wang; Victor G Prieto; Jeffrey E Gershenwald; Qingyi Wei; Elizabeth A Grimm
Journal:  Clin Cancer Res       Date:  2010-10-25       Impact factor: 12.531

2.  Mortality after uveal and conjunctival melanoma: which tumour is more deadly?

Authors:  Emma Kujala; Seppo Tuomaala; Sebastian Eskelin; Tero Kivelä
Journal:  Acta Ophthalmol       Date:  2008-10-15       Impact factor: 3.761

3.  Management of conjunctival malignant melanoma: a review and update.

Authors:  James R Wong; Afshan A Nanji; Anat Galor; Carol L Karp
Journal:  Expert Rev Ophthalmol       Date:  2014-06

4.  A Retrospective Review of Conjunctival Melanoma Presentation, Treatment, and Outcome and an Investigation of Features Associated With BRAF Mutations.

Authors:  Ann-Cathrine Larsen; Christina M Dahmcke; Christina Dahl; Volkert D Siersma; Peter B Toft; Sarah E Coupland; Jan U Prause; Per Guldberg; Steffen Heegaard
Journal:  JAMA Ophthalmol       Date:  2015-11       Impact factor: 7.389

5.  Mutations in GNA11 in uveal melanoma.

Authors:  Catherine D Van Raamsdonk; Klaus G Griewank; Michelle B Crosby; Maria C Garrido; Swapna Vemula; Thomas Wiesner; Anna C Obenauf; Werner Wackernagel; Gary Green; Nancy Bouvier; M Mert Sozen; Gail Baimukanova; Ritu Roy; Adriana Heguy; Igor Dolgalev; Raya Khanin; Klaus Busam; Michael R Speicher; Joan O'Brien; Boris C Bastian
Journal:  N Engl J Med       Date:  2010-11-17       Impact factor: 91.245

6.  Genetic Background of Iris Melanomas and Iris Melanocytic Tumors of Uncertain Malignant Potential.

Authors:  Natasha M van Poppelen; Jolanda Vaarwater; Hardeep S Mudhar; Karen Sisley; Ian G Rennie; Paul Rundle; Tom Brands; Quincy C C van den Bosch; Hanneke W Mensink; Annelies de Klein; Emine Kiliç; Robert M Verdijk
Journal:  Ophthalmology       Date:  2018-01-19       Impact factor: 12.079

7.  Time trends in the incidence of conjunctival melanoma in Sweden.

Authors:  E Triay; L Bergman; B Nilsson; C All-Ericsson; S Seregard
Journal:  Br J Ophthalmol       Date:  2009-07-23       Impact factor: 4.638

8.  Multicenter, International Assessment of the Eighth Edition of the American Joint Committee on Cancer Cancer Staging Manual for Conjunctival Melanoma.

Authors:  Puneet Jain; Paul T Finger; Bertil Damato; Sarah E Coupland; Heinrich Heimann; Nihal Kenawy; Niels J Brouwer; Marina Marinkovic; Sjoerd G Van Duinen; Jean Pierre Caujolle; Celia Maschi; Stefan Seregard; David Pelayes; Martin Folgar; Yacoub A Yousef; Hatem Krema; Brenda Gallie; Alberto Calle-Vasquez
Journal:  JAMA Ophthalmol       Date:  2019-08-01       Impact factor: 7.389

9.  Mutation frequencies of GNAQ, GNA11, BAP1, SF3B1, EIF1AX and TERT in uveal melanoma: detection of an activating mutation in the TERT gene promoter in a single case of uveal melanoma.

Authors:  M Dono; G Angelini; M Cecconi; A Amaro; A I Esposito; V Mirisola; I Maric; F Lanza; F Nasciuti; S Viaggi; M Gualco; R Bandelloni; M Truini; D A Coviello; S Zupo; C Mosci; U Pfeffer
Journal:  Br J Cancer       Date:  2014-01-14       Impact factor: 7.640

10.  Conjunctival melanoma with orbital invasion and liver metastasis managed with systemic immune checkpoint inhibitor therapy.

Authors:  Michael Chang; Sara E Lally; Lauren A Dalvin; Marlana M Orloff; Carol L Shields
Journal:  Indian J Ophthalmol       Date:  2019-12       Impact factor: 1.848

View more
  2 in total

1.  Local recurrence of uveal melanoma and concomitant brain metastases associated with an activating telomerase promoter mutation seven years after secondary enucleation.

Authors:  Jacob S Heng; Brittany M Perzia; John H Sinard; Renelle Pointdujour-Lim
Journal:  Am J Ophthalmol Case Rep       Date:  2022-06-01

2.  Identification of New Vulnerabilities in Conjunctival Melanoma Using Image-Based High Content Drug Screening.

Authors:  Katya Nardou; Michael Nicolas; Fabien Kuttler; Katarina Cisarova; Elifnaz Celik; Mathieu Quinodoz; Nicolo Riggi; Olivier Michielin; Carlo Rivolta; Gerardo Turcatti; Alexandre Pierre Moulin
Journal:  Cancers (Basel)       Date:  2022-03-19       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.